Pre-Made Tamtuvetmab biosimilar, Canine Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Tamtuvetmab benchmark antibody ( Canine Whole mAb, anti-CD52 therapeutic antibody, Anti-HE5/CDW52/EDDM5 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-548
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Tamtuvetmab biosimilar, Canine Whole mAb, Anti-CD52 Antibody: Anti-HE5/CDW52/EDDM5 therapeutic antibody |
---|---|
INN Name | Tamtuvetmab |
Target | CD52 |
Format | Canine Whole mAb |
Derivation | Chimeric (Dog/Rat) |
Species Reactivity | Canine |
CH1 Isotype | IgG2 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Unknown |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | 1bfo:HG:FE:BA:DC |
Year Proposed | 2015 |
Year Recommended | 2016 |
Companies | Aratana Pharmaceuticals |
Conditions Approved | NA |
Conditions Active | Canine T-cell lymphoma |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | CD52 |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide